KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Interest Expenses: 2017-2024

Historic Interest Expenses for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to $11.1 million.

  • Aquestive Therapeutics' Interest Expenses fell 0.04% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year increase of 4.76%. This contributed to the annual value of $11.1 million for FY2024, which is 75.51% up from last year.
  • Aquestive Therapeutics' Interest Expenses amounted to $11.1 million in FY2024, which was up 75.51% from $6.3 million recorded in FY2023.
  • Aquestive Therapeutics' 5-year Interest Expenses high stood at $11.1 million for FY2024, and its period low was $6.3 million during FY2023.
  • For the 3-year period, Aquestive Therapeutics' Interest Expenses averaged around $8.0 million, with its median value being $6.6 million (2022).
  • As far as peak fluctuations go, Aquestive Therapeutics' Interest Expenses plummeted by 34.80% in 2022, and later soared by 75.51% in 2024.
  • Yearly analysis of 5 years shows Aquestive Therapeutics' Interest Expenses stood at $11.1 million in 2020, then decreased by 9.17% to $10.0 million in 2021, then crashed by 34.80% to $6.6 million in 2022, then fell by 3.28% to $6.3 million in 2023, then skyrocketed by 75.51% to $11.1 million in 2024.